CVSI Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 18:16):

Stats
Šios dienos apimtis	42 994.00
Vidutinė apimtis	273 218
Rinkos kapitalizacija	7.13M
EPS	$0 ( 2024-03-27 )
Kita pelno data	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	2.18
ATR14	$0.00100 (2.29%)

Insider Trading

Date	Person	Action	Amount	type
2023-03-15	Dowling Joseph D	Buy	2 500 000	Employee Stock Option (right to buy)
2023-03-15	Grasser Joerg	Buy	1 250 000	Employee Stock Option (right to buy)
2022-10-21	Mccorkle William	Buy	500 000	Employee Stock Option (right to buy)
2022-10-21	Mccorkle William	Buy	0
2022-10-21	Mccorkle William	Buy	0

INSIDER POWER
100.00
Last 97 transactions
Buy: 17 580 526 \| Sell: 13 733 278

CV Sciences, Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

CV Sciences, Inc. Koreliacija - Valiuta/Žaliavos

0.73
( moderate )

0.72
( moderate )

0.00
( neutral )

-0.48
( neutral )

CV Sciences, Inc. Finansinės ataskaitos

Annual	2023
Pajamos:	$16.00M
Bruto pelnas:	$7.09M (44.27 %)
EPS:	$0.0201

FY	2023
Pajamos:	$16.00M
Bruto pelnas:	$7.09M (44.27 %)
EPS:	$0.0201

FY	2022
Pajamos:	$16.21M
Bruto pelnas:	$5.55M (34.25 %)
EPS:	$-0.0595

FY	2021
Pajamos:	$20.05M
Bruto pelnas:	$8.62M (42.98 %)
EPS:	$-0.140

Financial Reports:

No articles found.

CV Sciences, Inc.

CV Sciences, Inc. operates as a life science company in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The Consumer Products segment develops, manufactures, and markets plant-based dietary supplements and hemp-based cannabidiol (CBD) products under the PlusCBD, ProCBD, HappyLane, CV Acute, CV Defense, and PlusCBD Pet brand names in various health care sectors, including nutraceutical, beauty care, specialty foods, and pet products. It sells its products through its websites, internet sales, elect distributors, brick and mortar retailers, and select e-tailers. The Specialty Pharmaceutical segment focuses on developing and commercializing cannabinoids to treat medical indications. This segment is developing drug candidate CVSI-007 that combines CBD and nicotine in treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.